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Background: The aim of this study was to establish a minimally invasive deﬁbrillation testing (DT)
protocol for patients with implantable cardioverter deﬁbrillators (ICDs).
Methods: Two different energy DTs were performed, immediately after (15 J-DT) and 7 days after (r10 J-
DT) device implantation, in 20 consecutive ICD implantation patients. Cardiac-troponin T (c-TNT) and
heart-type fatty acid binding protein (H-FABP) levels were measured before implantation, 2 h after
implantation, and 1 day after each DT. For an additional 122 patients with ICD, we retrospectively
analyzed 203 DTs immediately and 7 days after device implantation.
Results: Serum c-TNT levels were signiﬁcantly elevated 2 h after 15 J-DT [0.008 (0.004–0.019) vs. 0.053
(0.037–0.068) ng/mL, po0.001], but not r10 J-DT [0.007 (0.004–0.018) ng/mL]. Similarly, serum H-FABP
levels were signiﬁcantly elevated 2 h after 15 J-DT (2.971.5 vs. 6.473.4 ng/mL, po0.001), but not
r10 J-DT (2.771.5 ng/mL). The changes in c-TNT and H-FABP levels between baseline and 2 h after DT
were signiﬁcantly greater for 15 J-DT compared with r10 J-DT [c-TnT: 0.039 (0.029–0.060) vs. 0 (0–
0.003) ng/mL, po0.001; H-FABP: 3.672.8 vs. 0.1671.1 ng/mL, po0.001]. The success rates of the
initial shocks delivered for ventricular ﬁbrillation were no different between r10 J-DT (85% [78/92]) and
Z15 J-DT (92% [103/111]).
Conclusions: Elevated levels of myocardial damage markers such as c-TNT and H-FABP were not found
after r10 J-DT. In addition, an acceptable success rate was conﬁrmed in r10 J-DT.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Implantable cardioverter deﬁbrillator (ICD) has become a
widely accepted therapy for patients with life-threatening ven-
tricular tachyarrhythmias [1–3]. However, it has been reported
that patients who received both appropriate and inappropriate
shocks had a substantially higher risk of death than those who did
not receive any [4]. This link between shock and poor clinical
prognosis has two possible explanations. The ﬁrst explanation is
that arrhythmia occurred more frequently during disease pro-
gression, resulting in increased mortality, [5] and the second
explanation is that shock therapy itself may worsen the clinical
outcome. Although it is difﬁcult to determine which of theseblished by Elsevier B.V. This is an
: þ81 23 628 5305.
p (T. Arimoto).explanations is correct, earlier animal and clinical studies revealed
that shock caused myocardial injury [6,7] and unstable cardiac
hemodynamics [8].
Deﬁbrillation testing (DT), conducted by inducing and termi-
nating ventricular ﬁbrillation (VF), has been widely considered
as a part of the standard protocol for ICD implantation. DT ensures
the device's ability to terminate VF, adequate sensing, and
appropriate high-voltage electrode connections. Although the
clinical importance of DT is still controversial [9–12], electro-
physiologists should reduce myocardial damage caused by DT as
much as possible.
The aim of this study was to investigate the extent of myo-
cardial injury after r10 J-DT and 15 J-DT. The levels of sensitive
and highly speciﬁc circulating biomarkers, cardiac troponin T (c-
TNT), and heart-type fatty acid binding protein (H-FABP), were
evaluated as indicators of myocardial injury [13,14]. In addition,open access article under the CC BY-NC-ND license
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Fig. 1. Blood sampling and deﬁbrillation testing protocols. Two different energy
deﬁbrillation testing were performed, immediately after and 7 days after device
implantation. Cardiac damage markers were measured before implantation, 2 h
after implantation, and 1 day after each deﬁbrillation testing. d, Day; DT, deﬁ-
brillation testing; h, hour.2. Materials and methods
2.1. Study population
Between March 2010 and February 2011, 20 consecutive
patients underwent pectoral ICD implantation at Yamagata Uni-
versity Hospital. Patients diagnosed with acute coronary syn-
dromes within 3 months preceding admission, and those with
renal failure, characterized by a serum creatinine concentration
42.0 mg/dL, were excluded from the study. Ethical approval was
obtained from the institutional review committee (approval date,
February 15, 2010; approval number, 147), and all patients pro-
vided informed, written consent before participating in the study.
To evaluate the success rate of r10 J-DT immediately after
device implantation, we identiﬁed 167 patients who underwent
pectoral ICD implantation between January 2004 and February
2010. Among these patients, we excluded 45 in whom DT was not
performed or who received several DTs immediately after device
implantation. The remaining 122 patients who underwent 203 DTs
were included in a retrospective analysis.
2.2. Deﬁbrillator implantation and DT
All 20 patients received a transvenous lead system via the
subclavian vein, and a pulse generator was placed in the left
pectoral region (Medtronic Inc., Minneapolis, MN, USA, n¼5; St.
Jude Medical Inc., St. Paul, MN, USA, n¼10; Boston Scientiﬁc Inc.,
Marlborough, MA, USA, n¼5). A single-chamber transvenous ICD
systemwas used for 10 (50%) patients. All patients were implanted
with a dual coil ICD lead at the right ventricular apex.
DTs examining two different energies were performed in each
patient. The ﬁrst DT (15 J-DT) was immediately after ICD implan-
tation, and the second DT [r10 J-DT (9 J or 10 J)] was performed
7 days after device implantation (Fig. 1). DTs were performed
under short-duration, deep sedation using thiopental. VF was
induced via the device's test program with a 50-Hz burst. In cases
of initial shock failure, the energy was increased in 10-J steps in
subsequent tests until deﬁbrillation was successful. In the retro-
spective analysis, which included 122 patients with ICDs, the
initial shock energy was selected by a physician who implanted
the device.2.3. Measurement of c-TNT and H-FABP
Baseline c-TNT and H-FABP levels were measured before ICD
implantation when the patient was stable and free from clinical
ventricular arrhythmia for at least 2 weeks. Blood sampling was
performed at least 1 week after electrophysiological studies and
VF induction. Postoperative blood samples were obtained 2 h and
1 day after the ﬁrst and second DTs.
Blood samples used to measure serum c-TNT and H-FABP levels
were centrifuged at 2500g for 15 min at 4 °C, within 30 min of
collection, and the serum was stored at 70 °C until analysis. The
concentrations of c-TNT were measured using a fourth-generation
electrochemiluminescence immunoassay on an Elecsys 2010
automatic analyzer (Elecsystroponin-T, Roche Diagnostics, Basel,
Switzerland) [13,14]. H-FABP levels were measured using a two-
step sandwich enzyme-linked immunosorbent assay (MARKIT-M
H-FABP, Dainippon Pharmaceutical Co. Ltd., Tokyo, Japan) [13,14].2.4. Statistical analysis
Continuous variables were expressed as the mean7the stan-
dard deviation. Skewed variables were presented as medians with
interquartile ranges (IQRs). We employed t-tests and chi-square
tests to compare continuous and categorical variables, respec-
tively. Mann–Whitney U tests were conducted for non-normally
distributed data, and Wilcoxon signed rank sum tests were used
for comparing pre- and postoperative values. Univariate analysis
and logistic regression were used to identify signiﬁcant predictors
of r10 J-DT failure. Values of po0.05 were considered statisti-
cally signiﬁcant.3. Results
3.1. Patient characteristics
All 20 patients underwent successful ICD implantation and
testing. The initial shocks were successful for both the ﬁrst (15 J-
DT) and second (r10 J-DT) sessions. No patients required addi-
tional shocks, and no serious complications were noted. The
clinical characteristics of the 20 patients for whom DTs and blood
sampling were conducted are shown in Table 1. The patients had a
mean age of 56.4712.2 years, and the majority (i.e., 80%, n¼16)
were male. Overall, 5 (25%), 2 (10%), and 7 (35%) patients had
hypertension, diabetes mellitus, and dyslipidemia, respectively.
Five patients had a history of ischemic heart disease. ICDs were
implanted for primary prevention in 5 patients and secondary
prevention in 15 patients. Three (15%) patients received a resyn-
chronization ICD device. The median plasma B-type natriuretic
polypeptide level was 51.9 pg/mL. The estimated glomerular ﬁl-
tration rate was preserved in all patients. Baseline c-TNT and H-
FABP levels were 0.008 (0.004–0.019) ng/mL and 2.971.5 ng/mL,
respectively. Echocardiography showed a preserved left ven-
tricular end-diastolic dimension and left ventricular ejection
fraction. Seven (35%) patients received amiodarone.
3.2. Myocardial injury
Serum c-TNT levels were signiﬁcantly elevated 2 h after 15 J-DT
[0.053 (0.037–0.068) ng/mL]; however, these value decreased
1 day after 15 J-DT [0.035 (0.021–0.053) ng/mL]. On the other
hand, serum c-TNT levels were not signiﬁcantly elevated 2 h after
r10 J-DT [0.007 (0.004–0.018) ng/mL] or 1 day after r10 J-DT
[0.007 (0.003–0.015) ng/mL] (Fig. 2A). The change in c-TNT level
from baseline to 2 h after DT was signiﬁcantly greater in 15 J-DT
compared with r10 J-DT [0.039 (0.029–0.060) ng/mL vs. 0 (0–
0.003) ng/mL, po0.001]. Normal values of c-TNT (r0.014 ng/mL)
were found in 14 of 20 (70%) patients at baseline. Nineteen (95%)
patients had an increase in c-TNT level (40.014 ng/mL) 2 h after
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normal c-TNT level (70% [14/20]). Similarly, serum H-FABP levels
were signiﬁcantly elevated 2 h after 15 J-DT (6.473.4 ng/mL), but
these value decreased 1 day after 15 J-DT (4.272.7 ng/mL). Serum
levels of H-FABP were not signiﬁcantly elevated 2 h or 1 day after
r10 J-DT, 2.771.5 and 2.671.4 ng/mL, respectively (Fig. 2B).Table 1
Baseline patient characteristics.
All patients (n¼20)
Age, yrs 56.4712.2
Female 4 (20)
Hypertension 5 (25)
Diabetes mellitus, n (%) 2 (10)
Dyslipidemia, n (%) 7 (35)
Diagnosis, n (%)
Ischemic heart disease 5 (25)
Non-ischemic heart disease 15 (75)
Device
Primary prevention, n (%) 5 (25)
Resynchronization ICD implanted, n (%) 3 (15)
Dual chamber ICD implanted, n (%) 10 (50)
Dual coil ICD lead, n (%) 20 (100)
Right-sided device implant, n (%) 0
Laboratory data
BNP, pg/mL (IQR) 51.9 (20.4–172.4)
eGFR, mL/min/1.72 m2 (IQR) 87.3 (75.3–93.0)
Troponin T, ng/mL (IQR) 0.008 (0.004–0.019)
H-FABP, ng/mL 2.971.5
Echocardiography
LV end-diastolic dimension (mm) 54.3710.1
LV ejection fraction (%) 55.3716.6
Drugs, n (%)
ACE inhibitor/ARB 10 (50)
β Blocker 7 (35)
Amiodarone 7 (35)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP,
B-type natriuretic polypeptide; eGFR, estimated glomerular ﬁltration rate; H-FABP,
heart-type fatty acid binding protein; ICD, implantable cardioverter deﬁbrillator;
IQR, interquartile range; LV, left ventricular.
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Fig. 2. Myocardial damage marker levels after deﬁbrillation testing (DT). (A) Serum leve
(0.037–0.068) ng/mL] but decreased 1 day after 15 J-DT [0.035 (0.021–0.053) ng/mL]. Ser
1 day after r10 J-DT [0.007 (0.003–0.015) ng/mL]. (B) Serum levels of heart-type f
(6.473.4 ng/mL) but decreased 1 day after 15 J-DT (4.272.7 ng/mL). Serum H-FABP le
(2.671.4 ng/mL).The change in H-FABP level from baseline to 2 h after DT was
signiﬁcantly greater for 15 J-DT compared with r10 J-DT (3.67
2.8 vs. 0.271.1 ng/mL, po0.001). A majority of patients [95%
(19/20)] showed normal H-FABP levels (r6.2 ng/mL) at baseline.
Ten (50%) patients showed an increase in H-FABP level
(46.2 ng/mL) 2 h after 15 J-DT; however, r10 J-DT did not affect
the prevalence of the normal H-FABP level (95% [19/20]).3.3. DT success rate
In our retrospective cohort of 122 patients with ICD implan-
tation, a total of 203 DTs were performed. Forty-one patients
underwent a single DT immediately after device implantation. The
remaining 81 patients underwent two DTs, one immediately after
device implantation and another 7 days after ICD implantation.
Among 122 patients, r10 J-DT and Z15 J-DT were performed in
76 (62%) and 46 (38%) patients, respectively. Among 203 DTs,
r10 J-DT and Z15 J-DT accounted for 92 (45%) and 111 patients
(55%), respectively. The success rate of r10 J-DT was 85% (78/92),
while that of Z15 J-DT was 92% (103/111). Although an acceptable
success rate was found for r10 J-DT, the success rate was rela-
tively low compared to that of Z15 J-DT (p¼0.07).3.4. Predicting r10 J-DT failure
The baseline characteristics of the 76 patients who underwent
r10 J-DT are summarized in Table 2. Hypertension, dyslipidemia,
and ischemic heart disease tended to be frequently observed in
the r10 J-DT success group (Table 2). No signiﬁcant difference
was found between the two groups in terms of age, prevalence of
resynchronization ICD implantation, dual chamber ICD, right-
sided device, blood examination, echocardiographic ﬁndings, or
amiodarone usage.0
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Table 2
Comparison of baseline characteristics between r10 J-DT successes and failures.
All patients
(n¼76)
Success
(n¼62)
Failure
(n¼14)
p Value
Age, yrs 60.5713.5 61.4712.9 56.6716.0 0.31
Female 21 (27.6) 19 (31.6) 2 (14.3) 0.22
Hypertension 12 (15.8) 12 (19.4) 0 0.07
Diabetes mellitus, n (%) 11 (14.5) 8 (12.9) 3 (21.4) 0.41
Dyslipidemia, n (%) 25 (32.9) 23 (37.1) 2 (14.3) 0.10
Diagnosis, n (%)
Ischemic heart disease 11 (14.5) 11 (17.7) 0 0.09
Non-ischemic heart
disease
65 (85.5) 51 (82.3) 14 (100) 0.86
Device
Primary prevention, n
(%)
28 (36.8) 25 (40.3) 3 (21.4) 0.19
Resynchronization ICD
implanted, n (%)
17 (22.4) 14 (22.6) 3 (21.4) 0.93
Dual chamber ICD
implanted, n (%)
50 (65.8) 43 (69.4) 7 (50.0) 0.17
Right sided device
implant, n (%)
3 (3.9) 2 (3.2) 1 (7.1) 0.50
Laboratory data
BNP, pg/mL (IQR) 127.4 (49.0–
345.1)
121.8 (46.0–
333.4)
135.3 (79.9–
426.9)
0.66
eGFR, mL/min/1.72 m2,
(IQR)
72.5 (50.4–
88.2)
72.5 (51.2–
87.9)
72.8 (50.9–
98.4)
0.77
Transthoracic
echocardiography
LV end-diastolic
dimension (mm)
57.5710.3 57.779.9 56.7712.3 0.78
LV ejection fraction (%) 45.7718.6 45.4718.4 47.1720.1 0.78
Drugs, n (%)
ACE inhibitor/ARB 46 (60.5) 38 (61.3) 8 (57.1) 0.77
β blocker 45 (59.2) 38 (61.3) 7 (50.0) 0.44
Amiodarone 35 (46.1) 28 (45.2) 7 (50.0) 0.74
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP,
B-type natriuretic polypeptide; eGFR, estimated glomerular ﬁltration rate; ICD,
implantable cardioverter deﬁbrillator; IQR, interquartile range; LV, Left ventricular.
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Our results demonstrated that patients who underwent ICD
implantation and received 15 J-DT exhibited evidence of myo-
cardial damage as indicated by increased serum c-TNT and H-FABP
levels. On the other hand, r10 J-DT (9 J or 10 J) was associated
with an acceptable successful DT rate and no signiﬁcant elevation
in either marker.
We used the speciﬁc myocardial injury markers c-TNT and H-
FABP. Some reports clearly show the clinical usefulness of c-TNT
among patients with myocardial infarctions [15,16] and cardiac
contusions [17]. In addition, H-FABP elevation is associated with
minimal damage to cardiomyocytes and reﬂects superﬁcial myo-
cardial injury. Basic and clinical research in rats, as well as human
autopsy analyses have revealed that H-FABP leakage occurs
despite the absence of myocyte necrosis [18]. H-FABP is a low-
molecular-weight protein that is normally conﬁned to the cyto-
plasm and released into the circulation through the porous
membranes of damaged myocardial cells [19,20].
There are some reports regarding the relationship between
internal shocks and myocardial injury. Hurst et al. reported that
mean deﬁbrillation energy during DT was signiﬁcantly higher in
patients with cardiac troponin I (c-TNI) elevation (20.073.8 J)
than in those without marker elevation (14.673.4 J). Multivariate
analysis revealed that a mean deﬁbrillation energy Z18 J was a
strong risk factor for a rise in c-TNI [6]. Boriani et al. conﬁrmed
asymptomatic, minor myocardial injuries in patients with persis-
tent atrial ﬁbrillation who underwent atrial cardioversion. In these
subjects, two catheters were placed in the right atrium and
the coronary sinus, respectively, to administer internal shocks.The level of c-TNI was elevated in 15 of 35 (43%) patients, and the
total delivered energy ranged from 28.7710.4 to 35.3732.6 J
[21]. In accordance with earlier reports, we found that both c-TNT
and H-FABP levels were elevated in patients undergoing 15 J-DT. If
myocardial damage only affected the limited focal myocardium, it
might not be a serious problem. However, endocardial shock
affects the entire heart. Schirmer et al. showed that in 13 fox
hounds, the use of endocardial lead systems with low-energy
countershocks caused severe myocardial alterations such as
swollen mitochondria, disruption of mitochondrial crests, and the
loss of integrity of the inner and outer mitochondrial membranes
[22]. Takano et al. assessed 17 patients with ICD implantation and
found a signiﬁcant correlation between shock strength and the
change in cardiac index; lower energy shocks did not affect cardiac
hemodynamics [8]. Although the precise relationship between
increased myocardial damage marker levels and altered hemody-
namic status is unclear, high-energy DT may induce focal myo-
cardial damage and affect cardiac hemodynamics.
Several studies concluded that neither ICD shock frequency nor
mortality was different between patients who underwent DT and
those who did not [10,12]. Conversely, patients who did not
undergo intraoperative DT had signiﬁcantly higher overall mor-
tality rates than those who did [9,11]. In addition to this con-
troversy, we need to consider the possibility of device malfunction.
A single successful DT for VF was just as useful as repeat DTs
[23,24]. Recently, sub-analysis of the Shockless IMPLant Evaluation
(SIMPLE) trial demonstrated that elevated troponin levels after ICD
implantation were associated with a high mortality rate (adjusted
hazard ratio 1.43, p¼0.001) and a high risk of arrhythmic death
(adjusted hazard ratio 1.80, p¼0.002). Abnormal troponin level
elevation was frequently observed in patients who underwent DT
(417 J) compared with those without DT (42.1% vs 37.5%, p¼0.04)
[25]. From this viewpoint, a single minimally invasive DT may be
acceptable.
Although the success rate for DT was not signiﬁcantly different
between r10 J-DT and Z15 J-DT, the former tended to have a
lower success rate. Minimally invasive DT is a promising strategy;
however, unsuccessful attempts are followed by the administra-
tion of additional higher energy DTs. Therefore, r10 J-DT should
be avoided in patients who may have a high risk for an unsuc-
cessful DT. Unfortunately, we could not identify speciﬁc risk factors
associated with an unsuccessful DT in the present investigation.
Earlier studies reported that atrial ﬁbrillation, left ventricular
systolic dysfunction, left ventricular hypertrophy, and amiodarone
usage were predictive of a high deﬁbrillation threshold [26,27].
4.1. Study limitations
First, DTs were performed twice in each patient. Myocardial
damage associated with the ﬁrst test (15 J-DT) may inﬂuence mar-
ker levels during the second test (r10 J-DT). Despite this, we found
that c-TNT and H-FABP levels were not increased after r10 J-DT.
Second, baseline blood sampling was performed before device
implantation, and not immediately before the ﬁrst DT. Although a
previous report concluded that cardiac marker levels did not
increase after lead implantation [5], device implantation itself
might have inﬂuenced myocardial damage markers in the present
study [6]. Third, all 20 patients who underwent blood sampling and
DT were implanted with a dual coil ICD lead in the present study.
The difference between single coil and dual coil ICDs may inﬂuence
myocardial damage. Finally, the SIMPLE study revealed the efﬁcacy
of ICD implantation without DT. However, in this study, all patients
were programmed for shocks of 417 J [12]. Future investigations
may be necessary to compare the efﬁcacies of ICD implantation
without DT versus those performed with minimally invasive DT.
D. Ishigaki et al. / Journal of Arrhythmia 32 (2016) 481–485 4855. Conclusion
Elevated levels of the myocardial damage markers c-TNT and
H-FABP were not found after r10 J-DT (9 J or 10 J) in patients who
underwent device implantation. Our ﬁndings conﬁrm that
minimally-invasive DT has an acceptable success rate. To prevent
unnecessary myocardium damage, r10 J-DT may be an ideal
strategy; however, it should not be used in patients at high risk for
a high deﬁbrillation threshold.Conﬂict of interest
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